Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Lupus ; 28(9): 1101-1110, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31291843

RESUMO

AIM: The aim of this study was to identify factors predictive of serious infections over time in patients with systemic lupus erythematosus (SLE). METHODS: A multi-ethnic, multi-national Latin American SLE cohort was studied. Serious infection was defined as one that required hospitalization, occurred during a hospitalization or led to death. Potential predictors included were sociodemographic factors, clinical manifestations (per organ involved, lymphopenia and leukopenia, independently) and previous infections at baseline. Disease activity (SLEDAI), damage (SLICC/ACR Damage Index), non-serious infections, glucocorticoids, antimalarials (users and non-users), and immunosuppressive drugs use; the last six variables were examined as time-dependent covariates. Cox regression models were used to evaluate the predictors of serious infections using a backward elimination procedure. Univariable and multivariable analyses were performed. RESULTS: Of the 1243 patients included, 1116 (89.8%) were female. The median (interquartile range) age at diagnosis and follow-up time were 27 (20-37) years and 47.8 (17.9-68.6) months, respectively. The incidence rate of serious infections was 3.8 cases per 100 person-years. Antimalarial use (hazard ratio: 0.69; 95% confidence interval (CI): 0.48-0.99; p = 0.0440) was protective, while doses of prednisone >15 and ≤60 mg/day (hazard ratio: 4.18; 95 %CI: 1.69-10.31; p = 0.0019) and >60 mg/day (hazard ratio: 4.71; 95% CI: 1.35-16.49; p = 0.0153), use of methylprednisolone pulses (hazard ratio: 1.53; 95% CI: 1.10-2.13; p = 0.0124), increase in disease activity (hazard ratio: 1.03; 95% CI: 1.01-1.04; p = 0.0016) and damage accrual (hazard ratio: 1.22; 95% CI: 1.11-1.34; p < 0.0001) were predictive factors of serious infections. CONCLUSIONS: Over time, prednisone doses higher than 15 mg/day, use of methylprednisolone pulses, increase in disease activity and damage accrual were predictive of infections, whereas antimalarial use was protective against them in SLE patients.


Assuntos
Hospitalização/estatística & dados numéricos , Infecções/epidemiologia , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Adulto , Antimaláricos/administração & dosagem , Estudos de Coortes , Relação Dose-Resposta a Droga , Feminino , Seguimentos , Glucocorticoides/administração & dosagem , Humanos , Imunossupressores/administração & dosagem , Infecções/etiologia , América Latina , Lúpus Eritematoso Sistêmico/fisiopatologia , Masculino , Metilprednisolona/administração & dosagem , Prednisona/administração & dosagem , Fatores de Proteção , Fatores de Risco , Índice de Gravidade de Doença , Adulto Jovem
2.
Lupus ; 27(4): 536-544, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28857715

RESUMO

Purpose The purpose of this paper is to determine the factors predictive of flares in systemic lupus erythematosus (SLE) patients. Methods A case-control study nested within the Grupo Latino Americano De Estudio de Lupus (GLADEL) cohort was conducted. Flare was defined as an increase ≥4 points in the SLEDAI. Cases were defined as patients with at least one flare. Controls were selected by matching cases by length of follow-up. Demographic and clinical manifestations were systematically recorded by a common protocol. Glucocorticoid use was recorded as average daily dose of prednisone and antimalarial use as percentage of time on antimalarial and categorized as never (0%), rarely (>0-25%), occasionally (>25%-50%), commonly (˃50%-75%) and frequently (˃75%). Immunosuppressive drugs were recorded as used or not used. The association between demographic, clinical manifestations, therapy and flares was examined using univariable and multivariable conditional logistic regression models. Results A total of 465 cases and controls were included. Mean age at diagnosis among cases and controls was 27.5 vs 29.9 years, p = 0.003; gender and ethnic distributions were comparable among both groups and so was the baseline SLEDAI. Independent factors protective of flares identified by multivariable analysis were older age at diagnosis (OR = 0.929 per every five years, 95% CI 0.869-0.975; p = 0.004) and antimalarial use (frequently vs never, OR = 0.722, 95% CI 0.522-0.998; p = 0.049) whereas azathioprine use (OR = 1.820, 95% CI 1.309-2.531; p < 0.001) and SLEDAI post-baseline were predictive of them (OR = 1.034, 95% CI 1.005-1.064; p = 0.022). Conclusions In this large, longitudinal Latin American cohort, older age at diagnosis and more frequent antimalarial use were protective whereas azathioprine use and higher disease activity were predictive of flares.


Assuntos
Antimaláricos/uso terapêutico , Glucocorticoides/uso terapêutico , Imunossupressores/uso terapêutico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Adolescente , Adulto , Fatores Etários , Antimaláricos/efeitos adversos , Estudos de Casos e Controles , Feminino , Glucocorticoides/efeitos adversos , Humanos , Imunossupressores/efeitos adversos , América Latina/epidemiologia , Modelos Logísticos , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/etnologia , Masculino , Análise Multivariada , Razão de Chances , Fatores de Proteção , Indução de Remissão , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
3.
J Psychosoc Nurs Ment Health Serv ; 35(2): 36-9, 1997 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-9044179

RESUMO

1. Beliefs and expectations inherent in theories are responsible for the formation of specific attitudes toward menopause and give direction to treatment. 2. Menopause is a complex process inclusive of sociocultural, psychological, and biological theories. 3. Nurses can play an active role in organizing women's educational support groups that address the inclusive theories of menopause, women's individual differences, and resources for treatment.


Assuntos
Menopausa , Modelos Biológicos , Modelos Psicológicos , Adaptação Psicológica , Feminino , Feminismo , Humanos , Menopausa/etnologia , Menopausa/fisiologia , Menopausa/psicologia
5.
Am J Nurs ; 91(1): 82, 1991 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-1984363
9.
Lupus ; 6(5): 445-8, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9229363

RESUMO

In order to assess the clinical characteristics and survival rate of pulmonary hemorrhage (PH) in systemic lupus erythematosus (SLE), we studied SLE patients who developed this complication. We found 34 patients within a total lupus cohort of 630 patients. All the patients had severe respiratory failure. We identified three different treatment regimens: (a) oral prednisone (1 mg/kg); (b) conventional methylprednisolone (3 g total dose) and (c) massive methylprednisolone (> 4 g). The overall survival rate was 38.2% and it was correlated with the massive regimen and early treatment (within the first 48 h after the onset of the acute event).


Assuntos
Doenças Autoimunes/complicações , Hemorragia/etiologia , Pneumopatias/etiologia , Lúpus Eritematoso Sistêmico/complicações , Administração Oral , Adulto , Antibacterianos/uso terapêutico , Doenças Autoimunes/tratamento farmacológico , Doenças Autoimunes/terapia , Estudos de Coortes , Comorbidade , Ciclofosfamida/uso terapêutico , Esquema de Medicação , Feminino , Hemoptise/etiologia , Hemorragia/tratamento farmacológico , Hemorragia/mortalidade , Hemorragia/patologia , Hemorragia/terapia , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/uso terapêutico , Pneumopatias/tratamento farmacológico , Pneumopatias/mortalidade , Pneumopatias/patologia , Pneumopatias/terapia , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Lúpus Eritematoso Sistêmico/terapia , Masculino , Metilprednisolona/administração & dosagem , Metilprednisolona/uso terapêutico , México/epidemiologia , Troca Plasmática , Plasmaferese , Pneumonia/tratamento farmacológico , Pneumonia/epidemiologia , Prednisona/administração & dosagem , Prednisona/uso terapêutico , Estudos Retrospectivos , Taxa de Sobrevida , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA